| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Yale University School of Medicine, New Haven, Connecticut 06510
| Abstract |
|---|
|
|
|---|
5-3ß-Hydroxysteroids in the
Adrenal and Ovary
5-3ß-hydroxy-steroids
5-3ß-hydroxysteroids | I. Introduction |
|---|
|
|
|---|
Biosynthetic studies demonstrated that steroid esters, specifically
acetates, can be produced artifactually during the isolation process.
The 3-acetate of 5
-androstane-3ß,17ß-diol was identified in
canine prostate and epididymis after arterial infusion of
[3H]testosterone but it was not formed enzymatically. The
steroid acetate was synthesized by transesterification in the solvent,
ethyl acetate, which was used for extraction of the tissue (11).
Likewise, dehydroepiandrosterone and 5-androstene-3ß,17ß-diol
(
5-androstenediol) acetates were isolated and
definitively identified by gas chromatography/mass spectroscopy
(GC/MS) after the incubation of large concentrations of
dehydroepiandrosterone (up to 100 µM) with mouse liver
homogenates (12). The acetylation appeared to be enzymatic since it did
not occur in heat-denatured tissues. However, the reaction was
dependent upon extraction of the incubation medium with ethyl acetate.
Apparently, an activated intermediate was formed that underwent
transesterification with the solvent. Subsequently, it has been shown
that biosynthetic acetylation can also result from esterase-catalyzed
transesterification of organic acetates added to the incubation (13).
Other nonenzymatic reactions that produce nonpolar products have also
complicated the detection of biosynthetic esters. When
18-hydroxycorticosterone is incubated with quartered rat adrenals, a
nonpolar product is formed (14) that has properties of an ester,
i.e., reversible hydrolysis. However, when characterized it
was unexpectedly found to be a dimer of aldosterone. Thus, the
detection of both endogenous and biosynthetic steroid esters was often
concealed by one or more of several confounding variables.
Nevertheless, as will be discussed below, there were early signs that
nonpolar steroid esters existed but they too were overlooked or
misinterpreted.
One of the first reports of the biological esterification of steroids was in 1964 when it was found that a nonpolar 14C-labeled metabolite was formed during incubations of [14C]testosterone with either dimethylbenzanthracene-induced rat mammary tumors, normal mammary glands of the pregnant rat, or a spontaneous mouse mammary tumor (15). This radioactive product was converted back into [14C]testosterone by hydrolysis, and it was identified as testosterone acetate by its mobility in several paper chromatography systems, as well as by cocrystallization with added carrier testosterone acetate. The possibility that the isolation process could have been responsible for nonenzymatic synthesis of the testosterone ester was eliminated. While the identification appears to have been carefully done, similar but more recent experiments have shown that testosterone is esterified with fatty acids, not acetate. The misidentification is likely a result of the chromatographic systems then available, which are not nearly as powerful as modern systems, and they probably could not completely resolve other alkyl esters. Furthermore, various alkyl esters often cocrystallize.
Other early studies reported that acetates of corticoids at C-21 are formed biosynthetically during the incubation of [3H]cortisol with homogenates of the brain of the neonatal rat (16). The evidence for enzymatic esterification was definitive. The enzyme was an acyl-Coenzyme-A transferase (acyl-CoA transferase) that showed specificity for natural corticoids since several synthetics such as triamcinolone were esterified at very low rates, if at all (17). Again, however, the identification of the biosynthetic esters as acetates was probably incorrect. Similar studies in rat mammary gland (18) and other tissues of the rat, including brain (19), using modern chromatographic and analytical techniques have definitively identified the nonpolar hydrolyzable corticoid metabolites as fatty acid esters and not acetates. The difficulty in characterizing the corticoid esters is discussed further below.
B. Sterol esters: substrates for the cholesterol side-chain
cleavage enzyme
The initial discovery of endogenous steroid fatty acid esters was
serendipitous, arising out of experiments that were concerned with
another family of steroid esters, the polar sulfate conjugates. In 1963
Seymour Liebermans laboratory (20) uncovered an interesting and
unexpected biochemical pathway. They observed that many of the
cytochrome P450 steroidogenic enzymes used steroid sulfates
as substrates, uncovering a previously unknown adrenal pathway to
dehydroepiandrosterone sulfate (20). Like the nonconjugated steroids,
polar sulfate conjugates were shown to be converted into
C21 and C19-steroid sulfates. Pregnenolone
sulfate is converted into dehydroepiandrosterone sulfate as well as
17
-hydroxypregnenolone sulfate (21). Later it was found that this
"sulfate pathway" extended to the first and critical steroidogenic
enzyme, the cholesterol side-chain cleavage enzyme. The amphipathic
sterol conjugate, cholesterol sulfate, is converted into pregnenolone
sulfate by soluble adrenal extracts (22), and intact mitochondria (23),
as well as in vivo (24). Cholesterol sulfate is a naturally
occurring lipid (25), which is formed by the sulfation of cholesterol
in a variety of tissues (26). Although the existence of the latter part
of the "sulfate pathway" from pregnenolone sulfate to
dehydroepiandrosterone sulfate was known, the enzymatic conversion of
cholesterol sulfate into a C21 sulfate product was
unexpected since even minor modifications of the A ring or its
substituents markedly decreases the ability of cholesterol analogs to
act as substrates for the cholesterol side-chain cleavage enzyme (27, 28). Consequently, it is surprising that the addition of a bulky and
charged sulfate ester would result in an excellent substrate for the
enzyme. This unusual specificity of steroidogenic enzymes for sulfate
conjugates affords a direct pathway from the C27 sterol
sulfate to the C19 conjugate, dehydroepiandrosterone
sulfate.
Experiments designed to study the specificity of the cholesterol side-chain cleavage enzyme led to the discovery that compounds with properties similar to fatty acid esters of steroids served as substrates for this steroidogenic enzyme. Model substrates of several C-3 derivatives of cholesterol were synthesized and incubated with an adrenal mitochondrial enzyme preparation to shed light on the structural requirements that permit cholesterol sulfate to act as a steroidogenic precursor (29). With only two exceptions, these analogs did not undergo significant C-20,22 cleavage. Only cholesterol sulfate and one unusual compound, cholesterol acetate, could serve as substrates. The C2 ester had been synthesized and tested under the expectation that it would serve as a negative control because it was widely believed that alkyl esters of cholesterol are not substrates for the cholesterol side-chain cleavage enzyme and that cholesterol esters in steroidogenic glands must first be hydrolyzed to cholesterol before they can serve in the steroidogenic pathway. Indeed, one of the first steps in the stimulation of steroidogenesis by tropic hormones is the mobilization of the cholesterol stores by activation of cholesterol esterase (30). Consequently, it was surprising that the 3ß-short chain acetate ester of cholesterol could serve as an excellent substrate for cholesterol side-chain cleavage enzyme, producing pregnenolone acetate at about the same rate at which cholesterol is converted into pregnenolone (29).
In light of this finding, several other cholesterol esters of
increasing chain length were synthesized and tested as steroidogenic
substrates. As the chain length of the acyl groups increased, the rate
of C-20,22 cleavage decreased up to C18, cholesterol
stearate, at which no appreciable cleavage was observed (Fig. 1
). However, cholesterol stearate could
act as an inhibitor, which indicated that it was capable of interacting
in some way with the cholesterol side-chain cleavage enzyme. This study
opened the possibility that some fatty acid esters of cholesterol could
serve as intermediates in steroidogenesis. Although it was clear that
at least two of the common fatty acid esters are not steroidogenic
substrates, the lipid droplets, the hallmark of steroidogenic organs,
contain a large variety of cholesterol fatty acid esters (31), many of
which could possibly serve as substrates for this putative pathway.
More recently, the C-20,22 cleavage of short-chain cholesterol esters
has been confirmed with a purified cholesterol side-chain cleavage
enzyme, eliminating the necessity of a separate enzyme for these esters
(32).
|
II. Lipoidal Derivatives of 5-3ß-Hydroxysteroids
in the Adrenal and Ovary
|
|---|
|
|
|---|
Since it was assumed that a unique steroidogenic pathway had been
uncovered, other experiments were performed to search for similar
nonpolar metabolites of steroidal products formed in this pathway,
including the lipoidal derivatives of other
5-3ß-hydroxysteroids, 17
-hydroxypregnenolone
(17
-HO-PL) and dehydroepiandrosterone (DL). Lipoidal derivatives of
both of these steroids were detected, and the presence of PL was
confirmed (34). In this study the ratio of lipoidal derivative to free
unesterified steroid was as follows: pregnenolone, 0.41;
dehydroepiandrosterone, 0.33; 17
-hydroxypregnenolone 0.1. Thus,
all the components of a nonpolar pathway to dehydroepiandrosterone are
present in the adrenal. With the possible exception of
17
-hydroxypregnenolone, the lipoidal derivatives are present in
sizable amounts well within the same order of magnitude as the free
steroid. Bélangers laboratory (35) confirmed that lipoidal
derivatives of the
5-3ß-hydroxysteroids are present in
the adrenal gland and extended this finding to several species. They
detected PL, DL, and the lipoidal derivative of
5-androstenediol. While the lipoidal derivatives are
present in smaller amounts than the free steroids (<40%) in most
animals, in man they exist in 3-fold greater concentration than their
unesterified form (Fig. 2
).
|
-pregnan-20-one (allopregnanolone) (36) were observed
in the hydrolyzed extract. Mass spectral analysis of the intact ester
fraction showed a heterogeneous family of fatty acid esters of the two
C21 steroids. The endogenous esters of both ovarian
steroids were mainly saturated; palmitate and stearate esters accounted
for 61% of the total. Later it was shown that homogenates from bovine
copora lutea catalyzed the esterification of pregnenolone to PL, but
the pregnenolone esters were not enzymatically reduced to
allopregnanolone esters (37). When progesterone was incubated with the
ovarian homogenate, it was reduced to allopregnanolone, which was then
esterified to the lipoidal derivative.
B. Biosynthetic esterification of
5-3ß-hydroxysteroids
It was originally suspected that the lipoidal derivatives of the
C21 and C19 steroids found in the adrenal and
ovaries were formed in a common biosynthetic pathway in which
hydrophobic lipoidal derivatives of steroidal intermediates were the
substrates. This hypothetical pathway was thought to originate with a
lipoidal derivative of cholesterol. However, another source of these
nonpolar metabolites was also possible: one in which each steroid is
converted into a lipoidal derivative. To explore the latter
possibility, adrenal mitochondrial and microsomal preparations were
incubated with dehydroepiandrosterone and pregnenolone. It was found
that indeed both were converted into lipoidal derivatives,
i.e., nonpolar metabolites that are transformed back into
the free steroid under hydrolytic conditions (38). Each of these
nonpolar steroidal metabolites was separable into several different
components, showing that both PL and DL were heterogeneous metabolites.
Subsequently, PL produced biosynthetically by incubation of
pregnenolone with adrenal mitochondria was purified by column
chromatography (including HPLC) and then analyzed by mass spectroscopy
(39). The spectra conclusively proved that PL is a family of fatty acid
esters. Five different esters were identified: palmitate, stearate,
oleate, linoleate, and arachidonate. Of the five esters, oleate and
arachidonate were present in the highest concentration, 42% and 34%
of the total, respectively. The fatty acid composition of PL differed
markedly from that previously reported for esters of the other major
lipids in adrenal mitochondria, indicating that there might be
specificity in the esterification of steroids.
Still the source of PL in the adrenal was unknown. It was unlikely that the fatty acid esters of pregnenolone that were identified could have been synthesized by the cholesterol side-chain cleavage enzyme since those esters of cholesterol are not substrates for the enzyme. However, the esters that were identified had been synthesized biosynthetically from pregnenolone, and it was possible that other members of the PL family existed. Another study was performed to isolate the endogenous adrenal PL by using as an internal standard [3H]PL prepared biosynthetically by incubation of [3H]pregnenolone with adrenal mitochondria (34). The biosynthetic [3H]PL, identified as fatty acid esters of pregnenolone (39), was added to an extract of bovine adrenal glands containing endogenous PL. The mixture was chromatographed on a column of Florisil. The fraction eluted from the column was counted to locate the [3H]PL internal standard. Then every fraction was hydrolyzed to analyze for endogenous PL by detecting released pregnenolone by two different techniques: 1) RIA and 2) identification of [14C]pregnenolone acetate after acetylation with [14C]acetic anhydride. Three distinct column fractions contained pregnenolone: only one migrated with the added [3H]PL, while the other two were considerably less polar. Consequently, only one of the three peaks was formed by direct esterification of pregnenolone. It was noted that the Florosil column had very poor resolving power, probably insufficient to separate compounds of similar structure. Thus, it is likely that the PL in the other two fractions is very different than the biosynthetic PL, which consists of several fatty acid esters. The PL in these other two fractions have not yet been identified. It is tempting to speculate that they were formed through C-20,22 cleavage of the corresponding metabolites of cholesterol. Nevertheless, currently there is no evidence supporting such a pathway.
The existence of other pathways involving lipoidal derivatives has been
investigated. For example, it was shown that fatty acid esters of
pregnenolone are, at best, only poor substrates for the 17-hydroxylase
enzyme. [3H]PL isolated from the incubation of
[3H]pregnenolone with adrenal mitochondria was incubated
with adrenal microsomes in the attempt to detect products of a pathway
to C19 lipoidal derivatives (40). Although small amounts of
17
-OH-PL and DL were found, their yield was so low that it is
unlikely that this pathway is physiologically significant. Similarly,
aromatase cannot convert testosterone fatty acid esters into estradiol
esters (41). Thus, it appears that steroidogenic pathways utilizing
fatty esters of steroids as substrates do not exist.
| III. Lipoidal Derivatives of Steroids in Peripheral Tissues |
|---|
|
|
|---|
Estradiol. The discovery of testosterone esterification and
the occurrence of adrenal lipoidal derivatives of the
5-3ß-hydroxysteroids increased the likelihood that
similar metabolites of other biologically active steroids might also
exist. To determine whether estrogens could be esterified,
[3H]estradiol (E2) was incubated with several
tissues of the rat. A nonpolar, saponifiable metabolite, the lipoidal
derivative of E2 (LE2) was detected in many of
the tissue extracts (43). The metabolite was found to have properties
that are consistent with estradiol esters at C-17: it was saponifiable,
resistant to oxidation, able to be acetylated (indicating the presence
of a free hydroxyl group), and less polar than estradiol-17-acetate.
Since the metabolite was protected from oxidation but had a free
hydroxyl, the site of esterification had to be C-17 and not the
phenolic C-3 hydroxyl group. This structure was also supported by the
finding that estrone, which does not have a hydroxyl at C-17, was not
enzymatically converted into a lipoidal derivative.
To characterize biosynthetic LE2, a relatively large amount
of E2,
29 mg, was mixed with
[3H]E2 as a marker and incubated with
180 g of bovine endometrial slices (44). The mixture was extracted
and an impure nonpolar fraction that weighed 400 mg and contained 0.8
µmol of [3H]LE2 was obtained by silica gel
chromatography. This fraction also contained most of the extracted
cholesterol. After subjecting the impure fraction to alumina
chromatography followed by reversed phase celite chromatography and
three separate HPLC systems, pure LE2 was isolated.
Reversed-phase HPLC separated LE2 into four distinct
fractions. Each of the LE2 fractions was characterized by
mass spectroscopy, which showed a family of E2 fatty acid
esters. The spectra also confirmed that the ester group is at C-17 and
not at the C-3 phenolic hydroxyl. The mass spectrum of the predominant
ester isolated in this study, E2 17-arachidonate, is shown
in Fig. 3
. A portion of each fraction was
transesterified and analyzed by GC/MS, which identified 11 different
fatty acid esters of estradiol. The fatty acids comprising
LE2 were predominantly unsaturated (86%) and remarkably
different from both the cholesterol esters and the phospholipids
present in the same tissue extract, another indication that specific
enzyme(s) might be involved in the esterification of the steroids.
|
5-androstenediol,
competitively inhibited esterification of E2, indicating
perhaps that they were all esterified by the same enzyme. However, the
inhibition might not have been specific since the KI of
each steroid was of low affinity, in the order of 50 µM.
In other studies the esterification of estradiol, as well as of many
other steroids, was detected in the human breast cancer cell line ZR-75
(49). The formation of the C-3,17-diester of E2 was
reported. Although we have attempted similar studies with this cell
line, we have not detected the formation of the diester.
Lee and Adams (50) found that testosterone is both a substrate for the
acyltransferase solubilized from bovine placenta and an inhibitor of
the esterification of estradiol, with a Km of 62
µM and a Ki of 72 µM,
respectively. This again indicates that the esterification is not
steroid specific. However, inhibition does not assure that both
substrates are esterified by the same enzyme, since estrone, which is
not esterified, is also a competitive inhibitor in this system (51).
Likewise, it had been suspected that the enzyme that esterifies
E2 as well as the
5-3ß-hydroxysteroids was
probably acyl-CoA:cholesterol acyltransferase (ACAT). In fact, it is a
different enzyme (52). Using rat liver microsomes as a model enzymatic
system, we found that the esterification of cholesterol and
dehydroepiandrosterone (as well as estradiol), all catalyzed by
acyl-CoA transferases, leads to steroidal esters with fatty acid
compositions different from the cholesterol esters. Furthermore, the
ACAT inhibitor, CL 277,082, blocked the esterification of cholesterol
almost completely, but had no effect on the esterification of the other
steroids. These studies conclusively demonstrated that ACAT is
different from the enzyme(s) that esterify the other steroids.
Many different tissues have been shown to synthesize LE2. We have found that LE2 is synthesized in various tissues of the rat (19). Lee and Adams solubilized the estradiol acyltransferase from the microsomal fraction of bovine placental cotyledons with sodium cholate (50). The solubilized enzyme was shown to be an acyl-CoA transferase with a Michaelis-Menten constant (Km) of 8 µM for E2. They found that a variety of long-chain fatty acid acyl-CoAs could serve as acyl donors and that many had widely varying affinities, with palmitoyl-CoA (C16:1) having the highest affinity, Km of 24 µM and arachidonoyl-CoA (C20:4) with the lowest affinity, Km of 330 µM. Interestingly, the affinity of the acyl-CoA fatty acids do not reflect the percentage of the various esters in LE2 that have been found in in vitro experiments (44, 46, 48, 53) including those utilizing bovine placental microsomes (51), probably indicating that the concentration of the specific acyl-CoA is the most important determinant.
Paris et al. (54) developed several reversed phase HPLC systems to characterize LE2, which they used to study the synthesis of the estrogen esters in bovine liver and adrenal microsomes (53). They confirmed that the enzyme is an acyl-CoA transferase and that the synthesized LE2 was composed mainly of five esters: arachidonate, linoleate, oleate, palmitate, and stearate. The relative composition of the esters was very different in the two tissues, reflecting the difference in the composition of fatty acids present in the tissues.
Vallet-Strouve et al. (55) made a provocative observation about LE2 biosynthesis in incubations with ovine myometrial cells that they had developed as a model of aging. As the cells were subcultured (aged), the oxidative metabolism of E2 decreased while the biosynthesis of LE2 dramatically increased. They interpreted this metabolic change to mean that as the cells aged, they switched over from enzymatic inactivation of E2 to its preservation through the synthesis of a storage form of estrogen.
Estriol. Estriol (E3) like estradiol, can be
converted into the lipoidal derivative, LE3. In incubations
of [3H]E3 with rat lung, a tissue that had
previously been characterized for LE2 synthesis (19), we
found that 2 radioactive nonpolar metabolites were formed, both having
properties of LE3 (Fig. 4
).
Further analysis showed that each was a family of D-ring fatty acid
esters, one at C-17ß (17ß-LE3) and the other at C-16
(16
-LE3). There was slightly more 16
-LE3
formed (57%). All of the various esters of both families were
separated by reversed-phase HPLC and identified by MS analysis. The
percent composition of the fatty acids comprising 16
-LE3
and 17ß-LE3 was found to be identical and to be the same
as LE2 synthesized in the same tissue, evidence that the
esterification of both positions in E3 as well as
E2 was probably the same. Again, esterification at the C-3
phenolic hydroxyl was not found, nor was a 16,17-diester formed. The
dramatic effect of fatty acid esterification on the estrogenic potency
of estriol is described below.
|
The biosynthetic conversion of corticosterone into a predominant ester,
oleate, was unexpected because the biological esterification of other
steroids invariably leads to a complex mixture of fatty acid
esters. Consequently, the biosynthesis of LE2 and the
corticosterone esters was compared in parallel incubations (19), and
their relative rate of synthesis was found to vary widely in different
tissues. It was confirmed that corticosterone is esterified principally
to corticosterone oleate (
80%) (Fig. 5
, bottom) and to other minor
esters in rat mammary tissue. However, in the same tissue,
E2 was converted into a heterogeneous mixture of at least
nine LE2-esters (Fig. 5
, top), a striking
contrast to the corticosterone esters. The oleate ester of
LE2 comprised only 18% of the total. In mammary tissue,
unusual medium chain (C8, C10, C12)
esters of LE2 were found, while none were measurable in the
corticosterone ester fraction. The esterified 5ß-reduced metabolite
of corticosterone was also isolated; it too was mainly the oleate
ester. The dissimilarity in the composition of the esters of
E2 and corticosterone was reproduced in incubations with
uterine tissue. Thus, the enzymatic process that produces
LE2 is different than the one that produces the corticoid
esters.
|
5-3ß-hydroxysteroids
5-androstenediol, has been the subject of
considerable interest due to its unusual estrogenic activity (60, 61, 62).
The possibility that esterification might be a mechanism by which this
weak estrogen could be concentrated and thus, increased in potency in
tissues, especially breast tumors, led Adams et al. (63) to
study the formation of the lipoidal derivative of this
C19-steroid in breast cells. Incubation of
5-androstenediol and dehydroepiandrosterone with human
breast tumor microsomes and various acyl-CoAs led to the formation of
lipoidal derivatives of both steroids (63). With
5-androstenediol, equal amounts of two nonpolar
metabolites were formed, both of which gave
5-androstenediol upon saponification. Different products
resulted if the
5-androstenediol esters were oxidized
first and then saponified. The more polar derivative was converted into
testosterone, indicating that the 17ß-hydroxyl was esterified and
that the 3ß-hydroxyl was free. The oxidation of the less polar
5-androstenediol ester led to dehydroepiandrosterone,
proving that it was a 3ß-monoester of
5-androstenediol. Although the microsomal preparation
could esterify
5-androstenediol at both C-3 and C-17,
the diester was not produced. These C-17 and C-3 esters were also
formed when
5-androstenediol was incubated with various
human breast cancer cell lines (MCF-7, ZR-751, MDA). In the
incubations with the cell lines, small amounts of a less polar
metabolite was formed, which was thought be the diester. After removal
of
5-androstenediol from the cells, the
concentration of the esters decreased slowly, and substantial amounts
were still present in the cells 24 h later.
Subsequent studies revealed that the ratio of the two types of esters,
C-17/C-3, varied markedly in different breast cancer cell lines (64)
and that the fatty acid composition of the esters produced in the
different cell lines also differed. Other studies of the esterification
of
5-androstenediol in ZR-751 cells demonstrated that
when the incubation medium was removed, most of the radioactive steroid
remaining in the cells was esterified (65). Continued incubation in the
absence of added steroid led to a new steady-state concentration of
free steroid that was produced by hydrolysis of the esters within the
cell. It lasted for a protracted period. These investigators reported
that both the C-17 and C-3 ester of
5-androstenediol
were formed, but they found that the C-3 hydroxyl was esterified at 5
times the rate of the C-17 hydroxyl. This contrasted with the previous
study in which the C-17 ester predominated in this cell line (64). Both
studies reported the formation of the diester of
5-androstenediol. However, the diester was not fully
characterized except by its mobility in TLC.
A wide variety of steroids including estrogens, glucocorticoids, and
androgens in addition to the
5-3ß-hydroxy-steroids
are converted into lipoidal derivatives in the ZR-751 cell line (49).
5
-Dihydrotestosterone (5
-DHT) was not esterified although it was
converted into 3
- and 3ß-reduced metabolites, which were
esterified. Testosterone was esterified. In addition, it was
metabolized by the 5
-reductase into 5
-DHT, and subsequently
converted into C-3 reduced metabolites, which were also esterified.
Considering that a variety of steroids, especially testosterone, were
esterified in these cells, it seems surprising that 5
-DHT is not a
substrate for the acyltransferase. These studies also confirmed that
the major ester of E2 is at C-17ß (the C-3 ester was not
formed). Traces of a metabolite with the chromatographic mobility of
the C-3,17ß-diester of estradiol were also detected. Although
esterification was not the major route of metabolism, it was noted that
the lipoidal derivatives of all of the steroids were the major
metabolites present in the cells. These investigators speculated that
their prevalence within the cell suggests a key physiological role.
Robel and Baulieu and their colleagues (66) studied the esterification
of pregnenolone and dehydroepiandrosterone in rat brain preparations.
As expected, most of the acyltransferase activity was present in the
microsomal fraction. The biosynthetic PL was isolated and identified as
fatty acid esters of pregnenolone (by GC after saponification). The
fatty acid composition of PL was compared with that previously reported
for the testosterone esters synthesized in rat brain in
vitro (42). Although there were significant differences in the
composition of the esters of these two steroids, the investigators did
not determine whether this is due to different enzymes or to different
experimental conditions. The PL synthesized in the brain was also
compared with the neutral lipids in the preparation; again, the fatty
acid composition was significantly different. Several other steroids,
including E2, testosterone, and 5
-DHT, were also shown
to be esterified. Interestingly, 5
-DHT is a substrate for the brain
acyltransferase but not for the enzyme in breast cancer cells (65).
E2 was esterified at the highest rate of the steroids
tested. Corticosterone, 17
-testosterone, and
17
-hydroxyprogesterone were not esterified. The highest levels of
acyltransferase activity were found in the 1- to 3-week-old rats. As
the animals aged, the activity decreased rapidly. The brains of
14-week-old animals contained only 14% of the enzyme activity in the
3-week-old rat brain. Whether the activity in other tissues also
decreased with age was not determined.
Smith and Watson (67) compared the acyltransferase activity in brain,
adrenal, kidney, and liver of sheep and rats (at 6 weeks old) using
pregnenolone and dehydroepiandrosterone as substrates. Brain tissue in
rat, but not in sheep, had the highest activity of the various tissues
with both steroids as substrates. In the sheep, the adrenal had the
highest activity when dehydroepiandrosterone was the substrate. With
pregnenolone as the substrate, the liver had the highest
acyltransferase activity, followed by the kidney. Whether this might
indicate that there are different enzymes in the tissues or different
enzymes for the two
5-3ß-hydroxysteroids is not yet
known.
C. Endogenous esters of sex steroids
We developed a sensitive GC/MS method to quantify LE2
(after saponification to E2) in tissue, using deuterated
estradiol stearate as an internal standard for correction of recovery
(10). The LE2 content was measured in several human
tissues. The steroid ester was detected mainly in fat, averaging about
250 pg/g in cycling females and about half that amount in menopausal
women. There was much less LE2 in muscle and none in urine.
The estrogen ester was also present in blood (LE2 in blood
and ovarian follicular fluid is described below) and in breast cyst
fluid, where it averaged about 26 pg/ml, about 10% of the
E2 concentration. Although the concentration of
LE2 in tissues and blood is much less than that of
E2, its striking potency (described below) indicates that
it could be a physiologically important store of hormone.
Paris et al. (68) investigated the formation of LE2 in vivo after the administration of E2. They injected large amounts of E2 (333 mg) mixed with [3H]E2 into a male calf for 3 days. Shortly after the last injection, the animal was killed and the 3H-labeled metabolites extracted from the perirenal fat were characterized. Approximately 25% of the radioactivity in the fat was present in the nonpolar fraction. Further purification by column chromatography including HPLC showed that the nonpolar metabolite was LE2. It is likely that, if a longer period had elapsed between the last injection and the analysis of the fat, most of the radioactivity would have been in the form of LE2. The investigators speculate that the presence of these long-lived steroids in fat could be used as a marker for the detection of estrogens a considerable time after estradiol is administered.
Spurred on by the assumption that testosterone esters would be very potent androgens, we investigated the existence of a lipoidal derivative of testosterone (TL) using rats as a model (69). We quantified endogenous TL by RIA after separation and saponification of the nonpolar fraction. We found sizable amounts of TL in fat (2.5 ng/g) and testes (4 ng/g) of male rats and none in the fat of females. There was no TL in any of the other tissues that were examined, including blood and brain. The immunoassayable material released from the TL fraction was confirmed as testosterone by GC/MS.
LE2, when exogenously administered, is metabolized at an
extremely slow rate (70). Since TL is present in much larger
concentrations in fat compared with LE2, the androgen
metabolite could be accurately measured. This allowed for the
determination of the rate of metabolism of this endogenous family of
steroid esters. When the disappearance of TL and testosterone from the
fat of male rats after castration was measured (Fig. 6
), most of the testosterone disappeared
from the fat in 3 h, and none could be detected by 6 h. In
contrast, 3 days after castration, the concentration of TL in fat had
decreased only slightly. Even after 1 week, the androgen ester was
still present. Thus, the rate of metabolism of TL was exceedingly slow
compared with that of "free" testosterone. Indeed, the slow rate of
catabolism of the endogenous esters of testosterone was even more
pronounced than that originally observed for exogenously administered
estradiol esters (70), and it confirms the existence of a protective
mechanism that potentiates the hormonal action of the lipoidal
derivatives (discussed below).
|
5-3ß-hydroxysteroids have been found in this tissue
(71), another indication of the specificity of the steroid
esterification. Although the search for LE2 in humans was
more limited (10) than that for TL in the rat, LE2 was also
found almost exclusively in fat, although it has been shown to be
synthesized in a variety of tissues (albeit of different species) (19).
It is not apparent how the sex steroid esters can be localized to fat,
as the enzyme system appears to be ubiquitous. While there are several
mechanisms that might account for this tissue specificity (different
rates of enzymatic hydrolysis and metabolism, different rates of
synthesis, different acyltransferases), there is no way to
differentiate among these possibilities at present. Since the C-17
esters are such poor substrates for esterase hydrolysis and thus
exceedingly long-lived, the first possibility seems to be the least
likely. However, the hydrophobic environment within adipocytes may aid
in the resistance to esterase enzymes, adding another layer of
complexity. The possibility that there might be different enzymes
capable of esterifying the 17-hydroxyl group is provocative. In this
view, the enzyme in fat could have a higher affinity than the enzyme in
other tissues and thus alone would be capable of the esterification of
low (physiological) levels of steroids. Multiple isozymes having
different Km values are well known in steroid biochemistry.
For example, there are at least two forms of the 11ß-dehydrogenase
(72, 73) and 5
-reductase (74, 75) enzymes, and the higher affinity
enzymes are extremely important in regulating the action of corticoids
and androgens, respectively. Nevertheless, the mechanism that results
in the differential accumulation of TL and LE2 is currently
not understood.
D. Androsterone esters in breast cyst fluid
Levitzs laboratory showed that androsterone is converted in
human breast tumor homogenates to a lipoidal derivative of
androsterone, i.e., a nonpolar and saponifiable metabolite
(76). This led them to search for this metabolite in human breast cyst
fluid since it is known to contain a variety of different steroids and
their metabolites (77). They found substantial amounts of the lipoidal
derivative of androsterone, averaging approximately 1.4 ng/ml. This
amounted to about 17% of the unesterified androsterone in the cyst
fluid. The lipoidal derivative was purified in several chromatographic
systems, including HPLC, where it migrated with the same retention time
as an authentic standard of an androsterone fatty acid ester. The HPLC
fractions were analyzed by negative chemical ion mass spectroscopy,
which clearly showed the mass ions (M-1)- of several
different esters as well as their corresponding carboxylate ions. The
relative amount of each ester was determined from these spectra by
normalizing the mass ions of equimolar solutions of standards. Six
different esters were detected; three of them, androsterone oleate
(49%), -linoleate (26%), and -palmitoleate (19%), accounted for more
than 90% of the total. The source of the androsterone esters was not
investigated. While it might be suspected that they are synthesized in
the breast cyst fluid by lecithin:cholesterol acyltransferase
(LCAT), this is unlikely since 3
-hydroxysteroids such as
androsterone are not esterified by this enzyme (78).
| IV. Lipoidal Derivatives Synthesized by Lecithin:Cholesterol Acyltransterase |
|---|
|
|
|---|
5-androstenediol 20, and estradiol 1. Testosterone,
5
-dihydrotestosterone, estrone, androstenedione, and
dehydroepiandrosterone sulfate were not esterified. Furthermore, they
demonstrated that lipoidal derivatives of the three
5-3ß-hydroxysteroids are present in human blood. Of
the three, the lipoidal derivative of pregnenolone (PL) is found in the
highest concentration, approximately 200 ng/100 ml in both men and
women. Dehydroepiandrosterone (DL) is 50 ng/100 ml, and that of
5-androstenediol is 10 ng/100 ml. Thus, the
concentrations of endogenous esters are proportional to their rates of
synthesis. It was found that blood DL was elevated in subjects with
acne and in hirsute women. Roy and Bélanger (80) found that
dehydroepiandrosterone was converted into a lipoidal derivative in
human serum and that most of the DL was bound to the lipoprotein
fraction. As suspected, the esterification was catalyzed by LCAT since
it was inhibited by the LCAT inhibitor, dithio-2-bis-nitrobenzoic acid
(DTNB). It has been recently shown that dehydroepiandrosterone and
pregnenolone are esterified by pure LCAT (81).
It appeared likely that the circulating lipoidal derivatives of
steroids in blood were synthesized there by LCAT. Lipoidal derivatives
did not seem to be secretory products. It had been previously noted by
all investigators that when lipoidal derivatives were synthesized by
tissues in vitro, they were invariably found only within
those cells and not in the incubation media. However, subsequent
studies of Bélangers group opened the possibility that the
esters may also be secreted by the adrenal (35). They found that after
treatment with ACTH, there was a rapid turnover of these esters in the
adrenal concomitant with a marked increase in the esters in blood.
While they recognized that the increase of the esters in blood after
ACTH administration could have been the result of increased substrate
in the blood due to secretion of free
5-3ß-hydroxysteroid from the adrenal, secretion of the
esters remained a possibility. However, their later experiments in rats
and guinea pigs showed that exogenously administered
5-3ß-hydroxysteroids were quickly converted into
circulating esters, another indication that the esters in blood are not
secretory products (82). The lipoidal derivatives formed in
vivo were present in the lipoprotein fractions, predominantly high
density lipoproteins (HDL) and low density lipoproteins (LDL). When the
lipoprotein fractions containing the esterified PL and DL were injected
into guinea pigs, they had a surprisingly rapid half-life in plasma,
about 40 min. Similarly, it was noted that when dehydroepiandrosterone
is esterified in human serum, almost all of the DL is in the
lipoprotein fractions and almost none is in the residual serum depleted
of lipoproteins (80).
When dehydroepiandrosterone is administered to humans by constant infusion, both dehydroepiandrosterone and DL levels increase in blood in such a way that the dehydroepiandrosterone/DL ratio remains constant (81), as would be expected if the DL in blood was formed in situ by LCAT. When insulin was administered concurrently with the steroid, the blood levels of both dehydroepiandrosterone and DL decreased. However, the LCAT esterification of dehydroepiandrosterone, but not cholesterol, as measured in blood in vitro, increased during insulin treatment. Thus, although dehydroepiandrosterone esterification increased with insulin treatment, the levels of DL decreased, evidence that insulin may increase tissue uptake of DL from blood. Bélanger et al. (83) also found that the concentration of DL in blood decreased with aging. The decrease in DL was much less than the age-related fall in dehydroepiandrosterone in blood. Thus, they speculated that although DL decreases with aging, the esterification of dehydroepiandrosterone actually increases.
In separate studies of the interaction of steroids with human
lipoproteins, several of the steroids appeared to bind in a
nonequilibrium manner (84). It was suspected that this might be an
indication of metabolism, esterification by LCAT. DL synthesized by
LCAT in the HDL3 fraction of human plasma was isolated and
characterized by single ion monitoring GC/MS (85). Although this
technique is very insensitive for steroid esters, nevertheless, it
clearly showed the presence of dehydroepiandrosterone linoleate.
Further studies (86, 87) showed that of the steroids dialyzed against
HDL, six of them, including dehydroepiandrosterone, pregnenolone,
5-androstenediol, estradiol, progesterone, and
5
-dihydrotestosterone, appeared to have an interaction indicative of
metabolism. Of these steroids, the first four were converted into
lipophilic products; progesterone and 5
-dihydrotestosterone were
not. The rate of esterification of the steroids was similar to that
previously reported (79). The products of the in vitro
incubations, PL and DL, were isolated, saponified, and analyzed by gas
chromatography. A large number of fatty acids were identified in the
saponified fraction. Because the fractions were assumed to be pure
(free of other kinds of esters), these results support the hypothesis
that the LCAT-synthesized PL and DL are fatty acid esters. As would be
expected for products of LCAT, the composition of fatty acids was the
same as that of cholesterol esters isolated from the same lipoprotein
fraction. Most importantly, the endogenous lipoidal derivatives, PL and
DL, present in fresh plasma were isolated from the HDL3
fraction and analyzed by GC/MS (87). The spectra definitively proved
that the lipoidal derivatives in blood were, as suspected, fatty acid
esters.
Recently, Bélangers group investigated the transfer of DL and PL in the lipoprotein fraction of blood (88). They noted that although steroids are esterified by LCAT in the HDL fraction, they accumulate in very low density lipoprotein (VLDL) and LDL as well as the HDL fractions. They presumed that the lipoidal steroids were transferred to the other lipoprotein fractions through the same mechanism that acts on lipoprotein-bound cholesterol esters. The sterol ester is transferred between lipoproteins by the cholesterol ester transfer protein (CETP) (89). However, when they incubated HDL fractions that contained biosynthetic esters of radioactive cholesterol, pregnenolone, or dehydroepiandrosterone with an acceptor VLDL fraction, they found that PL and DL were transferred to VLDL regardless of whether CETP was added. Contrariwise, the addition of CETP was required for the transfer of cholesterol esters from HDL to VLDL. Furthermore, an antibody to CETP inhibited the transfer of HDL-bound cholesterol esters to other lipoprotein fractions, but it did not affect the transfer of HDL-bound DL and PL. Thus, the transfer of the steroid esters within lipoprotein fractions is different from that of cholesterol esters and does not require the intervention of a transfer protein.
Our laboratory investigated whether LE2 circulated in human female blood. A nonpolar fraction was isolated from serum extracts, and the E2 released after saponification was measured by RIA (90). Although we detected LE2, its concentration could not be accurately quantified because of the high background that was created by the various required manipulations of the extracts. Jones and James (79) did not detect LE2 in female blood, although they recognized that they did not have the internal standard necessary to assess chromatographic mobility, recovery, etc. They did find, however, that E2 is a substrate for LCAT, which would be essential for LE2 synthesis in blood. Subsequently, we reinvestigated this question using the GC/MS technique (10) and confirmed that LE2 is indeed in blood, albeit in lower amounts than we previously estimated: 26 pg/ml in cycling females and 1325 pg/ml in gonadotropin-stimulated women. The amount of LE2 in blood is considerably lower than circulating E2: 222% of E2 in cycling women and about 1% in the gonadotropin-stimulated women.
TL has been reported in the blood of human males (91, 92), but it is likely that some other substance might have cross-reacted in the RIA that was used in those experiments. We have not been able to find TL in human blood after performing a number of experiments (our unpublished results). Bélanger et al. could not detect TL in the blood of rats and guinea pigs, even under conditions (androstenedione implants) that produce a dramatic increase in circulating testosterone (82). We also did not detect TL in male rat blood (69). Consequently, it appears that while the estrogen ester, LE2, circulates in blood, this same metabolite of the androgen, TL, does not. The difference between the two C-17 esters, LE2 and TL, is consistent with the substrate specificity of the LCAT enzyme, which esterifies steroids in blood. That is, estradiol, but not testosterone, is esterified by this enzyme (79).
Large amounts of corticosteroid acetates, including cortisol acetate, have been reported to circulate in human blood (93, 94). This is rather unexpected given the characterization of the corticoid esters as fatty acid esters, their low rate of esterification (18, 19, 52), and their rapid hydrolysis (95), especially the hydrolysis of steroid acetates (70). There is currently no published confirmation and, as explained in the Introduction, there is reason to be concerned about the possibility of an artifactual explanation for those findings.
B. Ovarian follicular fluid
Roy and Bélanger (96) reported that ovarian follicular fluid
obtained from subjects treated with gonadotropins contained PL
(identified by RIA after saponification). The endogenous PL was
isolated and analyzed by GC/MS. While they could not obtain the mass
ions of the intact esters (the major signal was M+ for
pregnenolone), this was not unexpected because mass spectra of the
intact esters are particularly difficult to acquire by GC/MS analysis.
However, they showed that PL migrated on HPLC with retention times
identical to several pregnenolone fatty acid esters. Later they found
that follicular fluid could catalyze the formation of PL from
[3H]pregnenolone and that the enzymatic esterification
was suppressed by the LCAT inhibitor, DTNB (97). The biosynthetic
3H-labeled PL was characterized as a family of fatty acid
esters (by HPLC analysis) whose composition was identical to that
reported for cholesterol esters in serum. Thus, like the steroid esters
in blood, PL in follicular fluid is synthesized by LCAT. They showed
subsequently that follicular fluid obtained from
gonadotropin-stimulated human ovaries contains more than 6
µM PL, over 1000 times greater than the concentration of
PL in blood (98). In fact, unlike blood, there is much more PL than
free pregnenolone in follicular fluid. Most of the PL in follicular
fluid is in the HDL fraction. They also made the interesting
observation that charcoal stripping, which adsorbs all of the free
steroid from follicular fluid, had no effect on the PL content. This
technique is universally used to remove steroids from plasma to produce
"steroid free" plasma. It is important to note that the lipoidal
derivatives of steroids cannot be removed by this procedure and that
significant amounts may be present that could be converted
enzymatically into biologically active hormones (see below).
LE2 is also present in relatively large amounts in human ovarian follicular fluid obtained from women stimulated with gonadotropins (99). The amount of LE2 in the follicular fluid, approximately 10-7 M, was far greater than its concentration in any other tissue and provided a source for the first isolation and characterization of an endogenous lipoidal derivative of a biologically active hormone. Five hundred milliliters of ovarian follicular fluid containing 4.4 µg of LE2 were extracted, and the LE2 fraction was purified by a combination of chromatographic separations including HPLC. Finally, the LE2 was resolved by reversed phase HPLC into five different fractions that were identified by mass spectral analysis as estradiol 17-fatty acid esters. The percent composition of the individual esters, as determined both by UV adsorption and RIA (as E2 after saponification), of the column fractions was: E2 17-linoleate, 37%; E2 17-palmitate, 25%; E2 17-oleate, 18%; E2 17-arachidonate, 17%; E2 17-stearate, 4%.
At first it was suspected that the LE2 was secreted from the ovary rather than synthesized in situ by LCAT since E2 is a poor substrate for LCAT and the concentration of LE2 is so high in the follicular fluid (almost the same as E2). Although the fatty acid composition was similar to that reported for the PL in follicular fluid (97) that was synthesized by LCAT, they were dissimilar enough to suggest that PL and LE2 might have been synthesized by different enzymes. Subsequently, when the comparison was made between the fatty acid composition of endogenous LE2 in several different follicular fluids and that of LE2 synthesized in vitro by LCAT in the same follicular fluid or in the subjects serum (100), they were the same. Furthermore, LE2 synthesized in ovarian cells isolated from the follicular fluid had a completely different composition. Thus, LE2, like PL in follicular fluid, is synthesized by LCAT. The relatively high concentrations of LE2 in follicular fluid is probably a result of the combination of the metabolic protection afforded by esterification, the closed environment of the ovarian follicle, and the inability of the lipoprotein-bound ester to diffuse out of the follicle. The role of LE2 in the ovarian follicular fluid is not known, but as will be discussed below, LE2 is a very potent estrogen that could have marked effects on the ovary.
| V. Steroid Esterases |
|---|
|
|
|---|
Banerjee et al. (104) have isolated an esterase from human
breast cyst fluid that acts upon estradiol esters. This protein, which
has a mol wt of
90 K and properties of a B type esterase, was shown
to cleave several C-17 esters of E2 including
E2 17-stearate, an ester representative of LE2.
Further analysis of breast cyst fluids from 367 women showed that the
esterase activity was present at widely different concentrations (105),
and only 39% showed significant activity. Since this enzyme would
serve to release free estrogens at specific regions of the breast, the
authors speculate that its presence could be a marker for the subset of
patients with fibrocystic disease who are at risk for developing breast
cancer. Lee et al. (106) have compared the esterase activity
of bovine placental cotyledons. They have found that throughout
purification, the ratio of esterase activity remained constant for
estradiol 17-oleate and the lipase substrate, monoacylglycerol.
Furthermore, the activity for both substrates decreased in parallel
when increasing concentrations of either HgCl2 or
phenylmethanesulfonyl fluoride were added as inhibitors. The results
indicate that the enzyme responsible for the hydrolysis of
LE2 in this tissue is hormone-sensitive lipase. It is
certain that lipase was in the enzyme preparation but, since the enzyme
was not pure, the possibility remains that another esterase specific
for LE2 might also have been present. Of course, the
likelihood that specific steroid ester hydrolases exist in other
tissues was not eliminated.
| VI. Lipoidal Derivatives of Steroid Hormones in Insects |
|---|
|
|
|---|
|
| VII. Biological Effects of Steroid Esterification |
|---|
|
|
|---|
-stearate and
17ß-stearate, injected subcutaneously in aqueous alcohol. The
16
-ester is slightly less potent than the 17ß-ester. This would be
expected since, unlike the 17ß-ester, the 16
-ester is not
sterically protected by the 18-methyl group and would be enzymatically
hydrolyzed more rapidly than E3 17ß-stearate. It is
interesting to note that while E3 is considered to be a
weak estrogen, its low potency due to rapid metabolism can be enhanced
by a sustained administration, closer to physiological conditions
(120). Apparently, exogenously administered LE3 can
maintain a long lasting E3 stimulus.
|
At the time of the discovery of LE2, there was some question of whether the estrogen esters could act directly at the level of the estrogen receptor. There had been several studies showing that analogs of short-chain E2 esters could bind to the estrogen receptor acting as affinity chromatography ligands or covalent affinity ligands that could compete with the binding of radioactive ligands for the receptor. However, it was shown that estradiol esters, including short-chain esters, do not bind to the estrogen receptor except at extremely high concentrations (122). Moreover, when E2 esters representative of LE2 are administered in vivo, it is E2 and not the esters that concentrate in the uterine nuclei (115). The activation of the estrogen receptor after the injection of estradiol esters parallels the kinetics of estradiol hydrolysis and accumulation in uterine nuclei (119). Thus, it is clear that the estrogen esters do not act directly at the level of the receptor. It therefore appears likely that the heightened action of LE2 is the result of an increased resistance to catabolism. We found that fatty acid esterification of E2 at C-17 increased the t1/2 in rats from 2 min for E2 to more than 6 h for the fatty acid esters of E2 (70). The nature of the ester was important as E2 17-stearate had almost a 60% longer t1/2 than E2 17-arachidonate. Metabolic protection of LE2 was also observed in humans (123). Interestingly, no effect was apparent on the in vivo rate of metabolism of short-chain esters of E2 in rats; E2 acetate and E2 hexanoate have about the same t1/2 as E2. Unlike the fatty acid esters comprising LE2, the short-chain esters are rapidly hydrolyzed (122). Consequently, it seems likely that the increased potency of the pharmacological short-chain E2-esters is due more to their increased solubility and slow release from the oil vehicle in which they are injected than to an inherent biological mechanism. Contrariwise, the biological esterification of the estrogens and androgens with fatty acids potentiates their hormonal actions through their innate resistance to enzymatic hydrolysis; the hydrophobic ester shields the steroid nucleus from catabolic enzymes.
B. Unique actions of the steroid esters in blood
Recently Shwaery et al. (124) made the interesting
finding of a relationship between LE2 formation in blood
and the antioxidant action of estrogens. Although it is widely
recognized that estrogen treatment reduces the age-related increase in
coronary artery disease in menopausal women, the mechanism is not
known. While it has been observed that estrogens can decrease the
in vitro oxidation of LDL thought to be implicated in
atherosclerosis, the inhibition is accomplished only with
supraphysiological (µM) concentrations of estradiol. Consequently, it
is generally thought that this direct action is not the mode by which
estrogens protect against coronary disease. Shwaery et al.
found that if male plasma was preincubated with E2, the LDL
fraction subsequently isolated was protected from oxidation. This
protection was apparent at 1 nM E2, an increase
in sensitivity of 1000-fold over the micromolar concentrations of
E2 usually required for in vitro protection of
LDL. When the isolated LDL fraction was analyzed, there was no residual
E2 present, only a nonpolar metabolite that was identified
as LE2. Most importantly, when the esterification of
E2 was blocked with the LCAT inhibitor DTNB, the protective
effect was eliminated. Although the mechanism is not yet known, it
appears that the esterification of physiological concentrations of
E2 can protect against LDL oxidation. Thus, the formation
of LE2 in blood may be a critical element in a nongenomic
effect of estrogens on the prevention of coronary artery disease.
Bélangers group provided evidence of a possible function for
the LCAT-synthesized esters of the
5-3ß-hydroxy-steroids (98). They hypothesized that
circulating lipoprotein-bound lipoidal derivatives of pregnenolone and
dehydroepiandrosterone could act as substrates for steroid synthesis
and under those circumstances supply hormonal precursors to tissues. It
occurred to them that previous reports of ovarian follicular fluid
enhancement of progesterone synthesis by granulosa cells might have
been caused by PL in the follicular fluid. They made the interesting
discovery that the HDL fraction from follicular fluid, but not HDL from
plasma, could partially restore progesterone synthesis in porcine
granulosa cells in which the cholesterol side-chain cleavage enzyme was
inhibited with 10 µM ketoconazole (Fig. 9
). Both the HDL from plasma and
follicular fluid had the same level of cholesterol esters, but only the
HDL from follicular fluid contained large amounts of PL. This
experiment opened up the possibility of HDL-bound PL being taken up by
the cells and converted into progesterone through the action of an
esterase (hydrolysis to pregnenolone), followed by the
5- dehydrogenase-isomerase (oxidation to progesterone).
In a more direct study they proved the existence of this pathway.
Porcine granulosa cells incubated with HDL or LDL labeled with
[3H]PL were shown to synthesize
[3H]progesterone. The synthesis of progesterone was
stimulated by FSH, implying that uptake or hydrolysis of the
lipoprotein-bound ester is under hormonal control. Chloroquine, an
inhibitor of lysosomal degradation, inhibited the formation of
unesterified steroids from [3H]PL-LDL. Excess unlabeled
HDL or LDL inhibited this reaction with both lipoprotein fractions
demonstrating that [3H]PL was taken up into the cells by
receptor-mediated internalization.
|
5-androstenediol. Thus,
circulating lipoprotein-bound steroid esters can be taken up into cells
and converted into free steroids. Apparently steroid esters can act as
a reservoir of biologically active hormones that no longer require the
cytochrome P450 steroidogenic pathway. | VIII. Conclusion |
|---|
|
|
|---|
5-3ß-hydroxysteroids. Some of the steroid esters,
namely those of E2, pregnenolone, and
dehydroepiandrosterone, circulate in blood. The esters are not secreted
into blood, but are made in situ by the esterification of
the free steroids. Interestingly, unlike ester synthesis in tissues,
the steroid esters in blood are synthesized by the same enzyme that
esterifies cholesterol, LCAT. In a manner that is completely different
from all of the other steroids and their metabolites, the esters in
blood are bound to lipoproteins. Like the esters synthesized in blood,
exogenously added steroid esters also bind to lipoproteins. Even short
chain estradiol 17-esters and corticoid-21-esters do not bind to the
plasma steroid binding proteins, sex hormone-binding globulin
and corticosteroid-binding globu-lin, respectively (126, 127).
The answer to the important question concerning the role that these
esters play is still uncertain, although accumulating evidence
indicates some unique actions. The studies of Bélanger have
demonstrated a unique pathway by which the steroid esters in blood are
taken up by cells through a lipoprotein receptor-mediated mechanism. By
contrast, the free steroids are generally thought to enter cells by
diffusion. In humans, cholesterol esters bound to LDL are taken up into
cells through the LDL receptor. The cholesterol esters synthesized by
LCAT are inserted into HDL and are transferred to LDL by CETP. This
transfer protein is not required for the movement of steroid esters
from HDL to LDL, and it is tempting to speculate that this facilitative
transfer provides some insight into the role that these esters play. It
has been shown that the
5-3ß-hydroxysteroid esters
that are taken up into cells are hydrolyzed and converted into active
4-3-ketones, e.g., PL is converted into
progesterone (in the adrenal the newly synthesized progesterone has
been shown to be converted into corticoids) and DL into testosterone.
Nonsteroidogenic cells containing the
5-3ß-ol-dehydrogenase-isomerase can also convert these
esters into active hormones. In this manner, these circulating steroid
esters can act as prohormones, and since they can be "activated" in
many tissues, there is a definite possibility of tissue-specific
stimulation. The unusual activity of these esters is evident by the
report of Shwaery et al. that the esterification of
estradiol in blood decreases the concentration of E2
required to inhibit LDL oxidation in vitro about 1,000-fold
over E2 by itself (124). The enormous micromolar
concentrations of estrogens that are required to inhibit in
vitro LDL oxidation led most endocrinologists to doubt that
E2 was of physiological significance in that capacity. The
finding that the esterification of physiological levels of
E2 produces the active agent, LE2, could have
an enormous impact on the understanding and treatment of
arteriosclerosis.
It is clear that the fatty acid esters of the sex steroids, androgens
and estrogens, like their short-chain pharmacological analogs, are
extremely potent hormones (Fig. 8
). Fatty acid esterification is one of
the few metabolic transformations that potentiate hormone action. In
addition, the esters are prohormones that require hydrolytic enzymes
for their activity. Their role in the physiology of the sex steroids is
not understood but it is evident from their long-lived action that they
may provide target tissue stimulation at times when steroidogenic
organs are quiescent and circulating steroid levels are low.
Tissue-specific stimulation is possible through the hydrolysis of sex
steroid esters (TL and LE2) and subsequent release of the
active hormone from neighboring fat. Paracrine communication by the
target tissue could activate specific esterases in adjacent fat,
leading to hydrolysis of esters and stimulation only of nearby target
organs. Finally, it is prudent to mention that these unusual steroids
might have other unforeseen actions. For example, the corticoid esters
are unlike other esters of biologically active steroids since they are
neither longer lived nor more potent corticoids. The existence of only
one specific ester may indicate that it is a specific message with
distinct hormonal properties. There is still a great deal about this
unusual family of steroids that is not understood, and hopefully more
will be revealed about them in the near future.
| Acknowledgments |
|---|
I gratefully acknowledge David Labaree and Linda OSullivan for their excellent help in the preparation of this manuscript. I am especially appreciative of the Herculean assistance of Wendy Kuohung.
| Footnotes |
|---|
1 Supported by NIH Grant 5-R01-CA37799. ![]()
2 The use of the letter "L" in this review
either as a prefix or suffix to name a specific steroid denotes the
term lipoidal derivative. Other investigators have used the phrase
lipoidal steroid, liposteroid, apolar metabolite, or acyl steroid to
name these nonpolar metabolites, which are now recognized as fatty acid
esters. ![]()
| References |
|---|
|
|
|---|
-androstane-3ß,17ß-diol by prostate and
epididymis. Steroids 24:261279[CrossRef][Medline]
-hydroxycholesterol in a preparation of hog adrenocortical
mitochondria. J Biochem (Tokyo) 66:5156
-dihydroxy-5-pregnen-20-one
and 3ß-hydroxy-5-androsten-17-one. J Steroid Biochem 11:13331340[CrossRef][Medline]
-pregnane-3,20-dione,
3ß-hydroxy-5
-pregnan-20-one, and its fatty acid esters by
preparations of bovine corpora lutea. Endocrinology 111:1723
5-androstene-3ß,17ß-diol with
estradiol and dihydrotestosterone receptors in human myometrial and
mammary cancer tissue. J Clin Endocrinol Metab 40:373379
5 adrenal steroids.
Endocrinology 127:27572762
5-sex steroids to long-chain fatty acids
in the ZR-751 human breast cancer cell line. J Biol Chem 2654:93359343
5-3ßHydroxysteroid acyl
transferase activity in the rat brain. Steroids 57:210215[CrossRef][Medline]
53ß-hydroxy
steroid acyl transferase activities in tissues of the male rat and
sheep. Steroids 62:422426[CrossRef][Medline]
-reductases. Proc Natl Acad Sci USA 87:36403644
-reductase 2 gene in male
pseudohermaphroditism. Nature 354:159161[CrossRef][Medline]
This article has been cited by other articles:
![]() |
F. Wang, W. Wang, K. Wahala, H. Adlercreutz, E. Ikonen, and M. J. Tikkanen Role of lysosomal acid lipase in the intracellular metabolism of LDL-transported dehydroepiandrosterone-fatty acyl esters Am J Physiol Endocrinol Metab, December 1, 2008; 295(6): E1455 - E1461. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Badeau, V. Vihma, T. S. Mikkola, A. Tiitinen, and M. J. Tikkanen Estradiol Fatty Acid Esters in Adipose Tissue and Serum of Pregnant and Pre- and Postmenopausal Women J. Clin. Endocrinol. Metab., November 1, 2007; 92(11): 4327 - 4331. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sonobe, T. Ohira, K. Ieki, S. Maeda, Y. Ito, M. Ajimura, K. Mita, H. Matsumoto, and M. N. Wilder Purification, Kinetic Characterization, and Molecular Cloning of a Novel Enzyme, Ecdysteroid 22-Kinase J. Biol. Chem., October 6, 2006; 281(40): 29513 - 29524. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Spagnuolo, L. Cigliano, L. D. D'Andrea, C. Pedone, and P. Abrescia Assignment of the Binding Site for Haptoglobin on Apolipoprotein A-I J. Biol. Chem., January 14, 2005; 280(2): 1193 - 1198. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Liere, A. Pianos, B. Eychenne, A. Cambourg, S. Liu, W. Griffiths, M. Schumacher, J. Sjovall, and E.-E. Baulieu Novel lipoidal derivatives of pregnenolone and dehydroepiandrosterone and absence of their sulfated counterparts in rodent brain J. Lipid Res., December 1, 2004; 45(12): 2287 - 2302. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hockerstedt, M. Jauhiainen, and M. J. Tikkanen Lecithin/Cholesterol Acyltransferase Induces Estradiol Esterification in High-Density Lipoprotein, Increasing Its Antioxidant Potential J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 5088 - 5093. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Lee and B. T. Zhu NADPH-DEPENDENT FORMATION OF POLAR AND NONPOLAR ESTROGEN METABOLITES FOLLOWING INCUBATIONS OF 17{beta}-ESTRADIOL WITH HUMAN LIVER MICROSOMES Drug Metab. Dispos., August 1, 2004; 32(8): 876 - 883. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vihma, A. Tiitinen, O. Ylikorkala, and M. J. Tikkanen Quantitative Determination of Estradiol Fatty Acid Esters in Lipoprotein Fractions in Human Blood J. Clin. Endocrinol. Metab., June 1, 2003; 88(6): 2552 - 2555. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Vihma, S. Vehkavaara, H. Yki-Jarvinen, H. Hohtari, and M. J. Tikkanen Differential Effects of Oral and Transdermal Estradiol Treatment on Circulating Estradiol Fatty Acid Ester Concentrations in Postmenopausal Women J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 588 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J Tikkanen, V. Vihma, M. Jauhiainen, A. Hockerstedt, H. Helisten, and M. Kaamanen Lipoprotein-associated estrogens Cardiovasc Res, November 1, 2002; 56(2): 184 - 188. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. J. Gruber, W. Tschugguel, C. Schneeberger, and J. C. Huber Production and Actions of Estrogens N. Engl. J. Med., January 31, 2002; 346(5): 340 - 352. [Full Text] [PDF] |
||||
![]() |
V. Vihma, H. Adlercreutz, A. Tiitinen, P. Kiuru, K. Wahala, and M. J. Tikkanen Quantitative Determination of Estradiol Fatty Acid Esters in Human Pregnancy Serum and Ovarian Follicular Fluid Clin. Chem., July 1, 2001; 47(7): 1256 - 1262. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Jendbro, C.-J. Johansson, P. Strandberg, H. Falk-Nilsson, and S. Edsbäcker Pharmacokinetics of Budesonide and Its Major Ester Metabolite after Inhalation and Intravenous Administration of Budesonide in the Rat Drug Metab. Dispos., April 13, 2001; 29(5): 769 - 776. [Abstract] [Full Text] |
||||
![]() |
H. Helisten, A. Höckerstedt, K. Wähälä, A. Tiitinen, H. Adlercreutz, M. Jauhiainen, and M. J. Tikkanen Accumulation of High-Density Lipoprotein-Derived Estradiol-17{beta} Fatty Acid Esters in Low-Density Lipoprotein Particles J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1294 - 1300. [Abstract] [Full Text] |
||||
![]() |
S. Xu, B. T. Zhu, and A. H. Conney Stimulatory Effect of Clofibrate and Gemfibrozil Administration on the Formation of Fatty Acid Esters of Estradiol by Rat Liver Microsomes J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 188 - 197. [Abstract] [Full Text] |
||||
![]() |
S. S. Kanji, W. Kuohung, D. C. Labaree, and R. B. Hochberg Regiospecific Esterification of Estrogens by Lecithin:Cholesterol Acyltransferase J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2481 - 2488. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |